Alcohol-associated liver disease (ALD) is a leading cause of preventable cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality, yet current laboratory and imaging tools detect only late-stage disease. This narrative review synthesizes emerging evidence on novel biomarkers that capture the multidimensional pathophysiology of ALD and discusses their utility for routine clinical practice. Traditional serum-based liver fibrosis markers (e.g., cytokeratin-18 fragments, Pro-C3, the enhanced liver fibrosis test) improve non-invasive staging risk beyond aminotransferases, while elastography techniques, such as vibration-controlled transient elastography and magnetic resonance elastography, can also quantify liver stiffness with high precision. Among novel mechanistic biomarkers, genetic polymorphisms in PNPLA3, TM6SF2, MBOAT7, HSD17B13, and polygenic risk scores define lifetime risk, whereas sex-specific hormonal milieus also modify susceptibility and progression. Moreover, gut dysbiosis signatures, including reduced Faecalibacterium prausnitzii, Akkermansia muciniphila, and a lower Firmicutes/Bacteroidetes ratio, and their metabolites (short-chain fatty acids, and bile acids, trimethylamine N-oxide) correlate with liver inflammation and fibrosis. Endocrine imbalances of cortisol, testosterone, and thyroid hormones further stratify metabolic vulnerability. Ultimately, multi-omics platforms (i.e., transcriptomics, lipidomics, proteomics, metabolomics, and epigenomics) can reveal distinct molecular signatures that predict steatohepatitis, fibrogenesis, and early HCC. Integrating these biomarkers enables phase-specific enrichment strategies, earlier intervention windows, adaptive dose-finding, and mechanismbased endpoints in ALD trials. Remaining challenges include assay standardization, validation across diverse cohorts, and incorporation into regulatory frameworks. Future work could evaluate cost-effectiveness and feasibility in routine clinical practice. Widespread adoption promises earlier diagnosis, personalized risk reduction, and more efficient drug development for this globally prevalent disorder.
Citations
Citations to this article as recorded by
Dendrobium nobile Lindl. alleviates acute alcoholic liver injury in mice by modulating bile acid metabolism via the enterohepatic circulation Di Wu, Qingping Yang, Ju Ye, Xuelan Chen, Xingdong Wu, Lin Qin, Yanliu Lu, Daopeng Tan, Yuqi He Journal of Ethnopharmacology.2027; 373: 122310. CrossRef
Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo Biology.2026; 15(2): 148. CrossRef
Review Article on: AI-Driven Precision Medicine in Liver Disease: Microbiome and Nanotechnology Integration Rahul Kumar, Amritesh Kumar, Aayush Kumar Tiwari, MD Nasiruddin Khan, Mohit Kumar, Moidul Islam Judder Pan-African Journal of Health and Psychological Sciences.2026;[Epub] CrossRef
N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials Mohamed Awad E. Ahmed, Mufreh Amin, Yomna Emad Abdalla, Amr Abdelghani, Nourhan Eid, Aya Samy, Omar Kassar, Khalid Radwan Alsaadany, Mohamed Ezzat M. Mansour BMC Psychiatry.2026;[Epub] CrossRef
Correspondence to editorial on “RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression” Xue-Wen Liu, Zi-Bin Zhan, Yu Gong, Ze-Hua Li, Kun-Hao Bai, Jun Weng Clinical and Molecular Hepatology.2026; 32(3): e349. CrossRef
Biomarkers From the Microbiome to Predict ALD Progression and Its Severity: A Comprehensive Review Suraj Mishra, Harshrajsinh Solanki, Palash Mandal, Jasbir Arora Mediators of Inflammation.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration’s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.
Citations
Citations to this article as recorded by
Quzhou-sourced Fructus Aurantii ameliorates MASLD by modulating glycolysis-dependent M1 polarization in hepatic macrophages Junbin Yan, Yunmeng Nie, Menglu Ding, Mi Zhou, Tingyuan Li, Sumei Xu, Shuo Zhang Phytomedicine.2026; 150: 157572. CrossRef
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation Leyi Wang, Xue Zhang, Yinggang Li, Min Zhao, Gang Xu, Zhenyu Duan, Qiyong Gong, Kui Luo Journal of Controlled Release.2026; 390: 114522. CrossRef
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Xiao‐Dong Zhou, Yusuf Yilmaz, Mazen Noureddin, Hung N. Luu, Ming‐Hua Zheng Alimentary Pharmacology & Therapeutics.2026; 63(6): 903. CrossRef
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, Giovanni Targher, Mark D Muthiah, Daniel Q Huang, Qin-Fen Chen, Mazen Noureddin, Wenhao Li, Vlad Ratziu, Rohit Loomba, Sven M Francque, Arun J Sanyal, Ming-Hua Zheng Gut.2026; 75(4): 815. CrossRef
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK‐Centric Analysis Seungchan Choi, Jin‐Seok Jung, Yie‐sung Seo, Sungmin Song, Jeehye Ham, Hannah Chung, Yousef Ramadan, Kangchan Choi Journal of Cellular and Molecular Medicine.2026;[Epub] CrossRef
Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis Rohit Loomba, Peter Chen-Yang Nikhil Daniel, Youxin Wang, Ricki Bettencourt, Egbert Madamba, Harris Siddiqi, Lisa Richards, Mildred D. Gottwald, Shibao Feng, Maya Margalit, Daniel Q. Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu npj Biofilms and Microbiomes.2026;[Epub] CrossRef
Artificial Intelligence, Real Results: AI Successfully Risk-Stratifies Patients with MASLD Cristian R. Perez, Mohamed A. Elfeki Digestive Diseases and Sciences.2026; 71(8): 3277. CrossRef
p53: from understanding its structure to advances in therapeutic targeting Wenhua Wang, Xia Liu, Hengqi Liu, Hassan Abolhassani, Han Yan, Huilai Zhang, Xianhuo Wang Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Jeny J Mendoza-Godoy, Luis A Concepción-Urteaga, Carlos O Martínez-Gutiérrez, José Paz-Ibarra World Journal of Hepatology.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Metabolic Pathways Linking Atherosclerotic Cardiovascular Disease With Metabolic Dysfunction-Associated Steatotic Liver Disease Koral S. E. Richard, Sumati Rohilla, Reethika Gade, Fabio Arias, Oren Rom Current Atherosclerosis Reports.2026;[Epub] CrossRef
Metabolism-modulating nanoparticles for remodeling adipose-liver crosstalk to reverse liver fibrosis Ling-Feng Zhang, Su-Qing Liang, Qing-Wen Huang, Jia-Wen Ru, Ze-Quan Ding, Chun-Yu Zhang, Yi Wang, Tian-Jiao Zhou, Lei Xing, Xian Wu Cheng, Yu-Kyoung Oh, Hu-Lin Jiang Journal of Controlled Release.2026; 395: 115026. CrossRef
The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed Gastroenterology Insights.2026; 17(2): 33. CrossRef
Health inequity and the risk of MAFLD/MASLD Ziyan Pan, Abdulla Al Hassani, Khalid M. AlNaamani, Yasser Fouad, Munira Y. Altarrah, Mohammed Eslam Clinical Nutrition ESPEN.2026; 74: 103355. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Insights into Metabolic-Inflammatory Dual-targeting Effects of Huangqi Guizhi Wuwu Decoction on Diabetic Hepatopathy via Regulation of the AMPK-FASN/PI3K-AKT Axis Sheng-Wen Lu, Qi-Qi Zhao, Zhi-Bo Wang, Si-Fan Guo, Ying Cai, Xian Wang, Dan-Dan Xie, Zhen-Cai Hu, Shi-Wei Wang, Ai-Hua Zhang, Yu Guan, Shi Qiu World Journal of Traditional Chinese Medicine.2026;[Epub] CrossRef
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH Caichen Zhong, Nana Boame, Semiu O. Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E. Rinella Expert Review of Pharmacoeconomics & Outcomes Research.2026; : 1. CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026; 41(9): 2913. CrossRef
Clinical pathophysiological and health system implications of the transition from NAFLD to MASLD: a narrative review Eslam Abady, Hazem AbuEl-Enien, Karrar Naem Karam, Sarim Hassan Shahab, Sarah Fakhiraldeen, Pari Kotak, Yahya Samadi, Zarqa Yasin Discover Medicine.2026;[Epub] CrossRef
Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography Jiahui Li, Hao Wu, Kevin J. Glaser, Fang-Shu Ou, Armando Manduca, Sudhakar K. Venkatesh, Claude Sirlin, Rohit Loomba, Vijay H. Shah, Richard L. Ehman, Alina M. Allen, Meng Yin Hepatology Communications.2026;[Epub] CrossRef
Kidney-alone transplantation in prior SLK candidates: a national registry analysis Beat Moeckli, Kevin B. Harris, Byron Smith, David Pereyra, Xiomara Benavides, Jody Olson, Alexander R. Cortez, Timucin Taner, Julie K. Heimbach, Douglas A. Simonetto, Samy M. Riad Transplant International.2026;[Epub] CrossRef
Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status Dong Yun Kim, Kyu-Na Lee, Kyung-Do Han, Beom Kyung Kim Biomedicines.2026; 14(9): 1985. CrossRef
Steatosis liver index: A validated machine learning model using clinical data distinguishes steatotic liver disease phenotypes Mangesh Pagadala, Talal Khurshid, Wanyu Zhang, Vatsalya Vatsalya, Craig J McClain, Maiying Kong, Winston Dunn, Ashwani K. Singal Digestive and Liver Disease.2026;[Epub] CrossRef
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts Nutrients.2025; 17(13): 2189. CrossRef
Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? Amedeo Lonardo, Ralf Weiskirchen Exploration of Drug Science.2025;[Epub] CrossRef
Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo International Immunopharmacology.2025; 166: 115539. CrossRef
Full Active Nanoplatform Restores ROS Homeostasis for Synergistic Therapy of Fatty Liver Disease via Dual Endogenous–Exogenous Pathways Ziyi Lin, Peng Xu, Yuehai Xu, Yixin Zheng, Huimin Li, Zixin Chen, Zhe Wang, Shaochen Song, Yuhao Liu, Zhao Yang, Ju Cui, Heyun Shen ACS Applied Materials & Interfaces.2025;[Epub] CrossRef
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma Dingwu Li, Xiang Zhang Hepatology Communications.2025;[Epub] CrossRef
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(1): e38. CrossRef
Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park Gut and Liver.2026; 20(4): 624. CrossRef
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study” Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH.
Citations
Citations to this article as recorded by
Modulation of PRL-1 in placental MSCs: A novel therapeutic strategy for hepatic fibrosis: Editorial on “Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal t Lihai Jiang, Wenjie Zheng Clinical and Molecular Hepatology.2026; 32(1): 377. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials Tripti Khare, Karina Liu, Lindiwe Oslee Chilambe, Sharad Khare International Journal of Molecular Sciences.2025; 26(1): 306. CrossRef
Hypoxia-inducible factor-1α inhibitor promotes non-alcoholic steatohepatitis development and increases hepatocellular lipid accumulation via TSKU upregulation Renli Zeng, Yuxin Wang, Jielu Wen, Zhipeng Cen, Tengyao Wang, Meng Duan, Xiuyi Huang, Zhengde Zhao, Zhongyu Zhang, Chuan Yang, Sifan Chen Archives of Biochemistry and Biophysics.2025; 765: 110313. CrossRef
Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches Emilio Merlo Pich, Ioannis Tarnanas, Patrizia Brigidi, Ginetta Collo Neurobiology of Stress.2025; 35: 100713. CrossRef
Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization Jialin Ren, Min Wu International Journal of Molecular Sciences.2025; 26(7): 3166. CrossRef
Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu Phytomedicine.2025; 141: 156654. CrossRef
Development and Validation of Machine Learning‐Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease Lushan Xiao, Lin Zeng, Jiaren Wang, Chang Hong, Ziyong Zhang, Chengkai Wu, Hao Cui, Yan Li, Ruining Li, Shengxing Liang, Qijie Deng, Wenyuan Li, Xuejing Zou, Pengcheng Ma, Li Liu Advanced Science.2025;[Epub] CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Herbal Combination of Angelica gigas, Zingiber officinale, and Aconitum carmichaeli Alleviates High Fat Diet‐Induced Non‐Alcoholic Fatty Liver Disease in Mice Through NRF2‐Mediated Regulation of Adipogenesis and Non‐Shivering Thermogenesis Harim Kim, Hye‐Lin Kim, Mina Boo, Hyunyoung Choi, Jaehyun Han, Seunghyun Nam, So Jung Kang, Jae Kyeom Kim, Yohan Han, Ji Hoon Jung, Woojin Kim, Kwan‐Il Kim, Jae‐Young Um, Jinbong Park, Leo E. Otterbein, Hyo In Kim, Seong‐Gyu Ko Food Science & Nutrition.2025;[Epub] CrossRef
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis Sudha S. Shankar, Samuel J. Daniels, Darren Robertson, Janeli Sarv, José Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun J. Sanyal Clinical Gastroenterology and Hepatology.2024; 22(9): 1847. CrossRef
Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease Mohamed N. Abdelnabi, Ghada S. Hassan, Naglaa H. Shoukry Frontiers in Immunology.2024;[Epub] CrossRef
An economically viable stable isotope-enhanced multiple reaction monitoring method for total fatty acid analysis in a mouse model of non-alcoholic fatty liver disease Zijia Zhang, Yawen Liu, Gaohan Li, Xiaoling Chen, Min Lei, Yang Zhou, Huali Long, Qinhua Chen, Jinjun Hou, Wanying Wu Journal of Chromatography A.2024; 1736: 465406. CrossRef
Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra Cells.2024; 13(24): 2055. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials Zijie Jin, Yan Yuan, Chen Zheng, Shijian Liu, Hongbo Weng Journal of Diabetes and its Complications.2023; 37(8): 108558. CrossRef
A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey Stan Driessen, Vivian D. de Jong, Koen C. van Son, Tatiana Klompenhouwer, Yann Colardelle, Marco Alings, Cristophe Moreno, Stefan D. Anker, Manuel Castro Cabezas, Adriaan G. Holleboom, Diederick E. Grobbee, Maarten E. Tushuizen United European Gastroenterology Journal.2023; 11(7): 654. CrossRef
Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma Rong Liu, Ming-Ping Qian, Ying-Yu Cui Metabolism.2023; 147: 155665. CrossRef
Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes Amedeo Lonardo Exploration of Drug Science.2023; : 239. CrossRef
Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan Chin-Hsiao Tseng Cancers.2023; 15(17): 4276. CrossRef
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień Medicina.2023; 59(10): 1789. CrossRef
Extracellular Superoxide Dismutase Attenuates Hepatic Oxidative Stress in Nonalcoholic Fatty Liver Disease through the Adenosine Monophosphate-Activated Protein Kinase Activation Heechul Nam, Ji Lim, Tae Kim, Eun Kim, Sae-Jong Oum, Si Bae, Cheol Park Antioxidants.2023; 12(12): 2040. CrossRef
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease Young Chang, Soung Won Jeong, Jae Young Jang Clinical and Molecular Hepatology.2023; 30(1): 129. CrossRef
First
Prev
